Compare RNST & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | INDV |
|---|---|---|
| Founded | 1904 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.2B |
| IPO Year | 1999 | 2014 |
| Metric | RNST | INDV |
|---|---|---|
| Price | $39.83 | $35.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $46.67 | ★ $49.50 |
| AVG Volume (30 Days) | 647.4K | ★ 2.2M |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | 1.88 | ★ 2.78 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | $11.39 | $7.50 |
| Revenue Next Year | $6.20 | $5.07 |
| P/E Ratio | $21.34 | ★ $12.59 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $33.04 | $27.68 |
| 52 Week High | $44.54 | $42.81 |
| Indicator | RNST | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 53.02 |
| Support Level | $38.84 | $32.90 |
| Resistance Level | $40.98 | $35.93 |
| Average True Range (ATR) | 0.80 | 1.41 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 36.61 | 68.87 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has two reportable segments: Community banks and Wealth management. With its Community Banks segment, the company provides a range of financial services to individuals and small businesses. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).